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Abstract 
Introduction: Data regarding the role of fibroblast growth factor 23 (FGF23) in primary hyperparathyroidism (PHPT) are scarce and 
discordant. Our study aimed to evaluate the prognostic impact of FGF23 upon the clinical and biochemical evolution of PHPT. 
Material and methods: Forty-two patients with ages between 30 and 80 years, diagnosed with PHPT caused by a sporadic, solitary 
parathyroid adenoma, and referred to surgery (minimally invasive parathyroidectomy) were prospectively included in the study. Serum 
levels of FGF23, PTH, 25(OH)D3, calcium (Ca), phosphate (P), total procollagen type 1 N-terminal propeptide, and C-terminal telopep-
tide of type I collagen were determined at baseline (preoperatory), one day after surgery, and in 13 patients also prospectively at three, 
six, and 12 months. Bone mineral density (BMD) was also evaluated before surgery in all patients and 12 months after surgery in the 13 
followed up patients.
Results: In the 42 PHPT patients with D hypovitaminosis (mean 25(OH)D3 levels of 16.2 ± 1.5 ng/mL), preoperatory serum FGF23 
concentration was within the normal range (75.55 ± 3.39 pg/mL) and remained unchanged one day post operation (81.69 ± 4.67 pg/mL, 
p = non-significant). The 13 patients followed prospectively for up to 12 months after surgery also showed unmodified FGF23 levels 
(80.9 ± 11.03 pg/mL, p = non-significant), despite PTH and Ca normalisation and vitamin D replenishment. Preoperatory FGF23 negatively 
correlated with PTH (r = –0.37, p = 0.038), but not with 25(OH)D3, Ca, P, bone mass, or metabolism markers. 
Conclusions: In PHPT, correlations between FGF23 and PTH seem rather an epiphenomenon. Therefore, we think that FGF23 evaluation 
and dynamics are not informative regarding PHPT severity. (Endokrynol Pol 2020; 71 (4): 306–312)
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Introduction
A recently described regulator of calcium (Ca) and phos-
phate (P) metabolism is osteocyte-synthesised fibroblast 
growth factor 23 (FGF23) [1]. Through activation of its 
specific receptor FGFR1 in the presence of klotho, FGF23 
downregulates the expression of sodium-P co-transport-
ers, thus inhibiting renal P reabsorption in the proximal 
renal tubule [2]. It also represses the transcription of the 
gene that encodes the 1-a-hydroxylase, the rate-limiting 
enzyme for calcitriol synthesis. FGF23 recently emerged 
as having sodium and chloride conservative functions 
also in the distal renal tubule, where it increases the 
expression of epithelial Ca channel TRPV5 and of 
sodium-chloride cotransporter [1].
The main regulators of Ca and P metabolism — para-
thyroid hormone (PTH), calcitriol and FGF23 — modu-
late each other’s synthesis in conditions of health and 
disease. Parathyroid hormone (PTH), calcitriol, and P 
stimulate FGF23 production and secretion, which in 
turn encompasses a genuine bone-kidney-parathyroid 
negative feed-back loop by downregulating all the 
above [2]. However, the FGF23-induced calcitriol 
downregulation may lead to an indirect elevation of 
PTH levels [3]. 
Primary hyperparathyroidism (PHPT) is a disorder 
characterised by increased serum PTH and calcitriol 
production — both positive stimuli for FGF23 syn-
thesis — and accompanied by hypophosphataemia 
and increased urinary P excretion — modifications 
also related to FGF23 [1, 2, 4, 5]. Despite this, very few 
studies have approached the secretory profile of FGF23 
and its role in the metabolic and bone pathophysiology 
of PHPT, which remains inconsistently defined [6–9]: 
apparently, mild elevations of serum FGF23 in PHPT 
have been reported in some studies before parathyroid-
ectomy with normalisation after surgery [6], but not in 
others [7]. Furthermore, experimental and also clinical 
data suggest bone direct autocrine/paracrine actions 
for FGF23, which is supposed not only to suppress 
bone formation and mineralisation via Wnt pathway 
inhibition and downregulation of tissue non-specific 
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participants and at 12 months follow-up for the remaining 13 
subjects. Bone mineral density (BMD) was measured by two ex-
perienced International Society for Clinical Densitometry certified 
technicians according to standard protocol. Due to the fact that the 
T-score was the same as the Z-score in the younger patients (men 
under 50 years of age and premenopausal women), but not in men 
over 50 years of age and postmenopausal women, the T-score was 
employed for all subjects.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 (SPSS version 
18.0 for Windows, IBM SPSS Inc.). Data are expressed as mean 
± standard error of the mean (SEM). Differences between pre-
operatory and post-operatory values were tested using the paired 
samples t-test, while ANOVA or the non-parametric Kruskal-Wallis 
test was employed for differences between three or more variables. 
Linear relationships between normally distributed variables were 
investigated with Pearson’s correlation coefficient, and non-normal-
ly distributed variables with Spearman’s correlation coefficient. The 
chi-squared test was employed to investigate associations between 
categorical variables. A p value < 0.05 was considered significant.
Results
The baseline characteristics of the study participants 
are shown in Table 1. The study group had a mean 
age of 54.6 ± 1.8 years and was composed primarily of 
women. Mean serum FGF23 concentration before sur-
gery was within the normal range (75.55 ± 3.39 pg/mL) 
alkaline phosphatase (TNAP) transcription, but also 
to act concurrently with PTH upon the expression of 
the receptor activator of nuclear factor kappa-b ligand 
(RANKL) on osteoblasts and thus promote bone resorp-
tion [1, 10, 11]. 
Our study aimed at evaluating the prognostic 
impact of FGF23 upon the clinical, biochemical, and 
histological evolution and severity of PHPT. 
Material and methods
Study design
Forty-two patients aged 30–80 years old, diagnosed with PHPT 
caused by a sporadic, solitary parathyroid adenoma, and referred to 
surgery (minimally invasive parathyroidectomy) between January 
and December 2015 were prospectively included in the study after 
giving their informed consent. The diagnosis of PHPT was estab-
lished biochemically (increased PTH levels associated with serum 
Ca above the upper normal reference value of 10 mg/dL on two 
subsequent measurements, increased urinary Ca, and creatinine 
clearance ≥ 90 mL/min/1.73 m2); the parathyroid adenoma was con-
firmed and localised via parathyroid scintigraphy (Tc99m+MIBI). 
Exclusion criteria were represented by the conservative treatment 
of the PHPT, secondary hyperparathyroidism, chronic kidney dis-
ease, parathyroid hyperplasia, the presence of multiple endocrine 
neoplasia and malignant hypercalcaemia. 
All 42 patients were evaluated at diagnosis (before parathyroidectomy 
— serum determinations, bone mineral density), during surgery 
(parathyroid adenoma volume), and at day 1 post operation (serum 
determinations), while 13 were followed prospectively at three, six, 
and 12 months after surgery for the same parameters. None of the 
patients experienced complications, such as severe hungry bone 
syndrome, after the parathyroidectomy. Informed consent was 
obtained from all individual participants included in the study. 
The study was approved by the local Ethics Committee (reference 
number 157/6.01.2015).
Serum determinations
Blood samples were collected at baseline (before surgery) and at day 
1 post operation for all patients; blood samples were also collected 
at three, six, and twelve months for 13 patients that presented for 
follow-up. For each patient, the serum was aliquoted and stored at 
–20°C until assessment, which was performed no later than three 
months after each visit. 
Serum and urine concentrations of Ca and P were determined via 
colorimetry using automated analysers (Cobas 6000, Roche). Serum 
FGF23 (C-terminal; SEA746Hu Wuhan USCN Business Co., Ltd.) 
and vitamin D levels (25(OH)D3; Immunodiagnostik AG, Bensheim, 
Germany) were determined via enzyme-linked immunosorbent 
assay (ELISA), while PTH (Elecsys PTH, Roche Diagnostics GmbH, 
Mannheim, Germany) and bone metabolism markers total procol-
lagen type 1 N-terminal propeptide (P1NP; SEA957Hu Wuhan 
USCN Business Co., Ltd.) and the C-terminal telopeptide of type 
I collagen (CTx; CEA892Hu Wuhan USCN Business Co., Ltd.) were 
measured via electro-chemiluminescence immunoassay (ECLIA). 
Intra-operatory adenoma volume
After surgical excision of the previously localised parathyroid 
adenoma, the craniocaudal, mediolateral, and anteroposterior 
diameters were measured, and the volume of the adenoma was 
calculated as an ellipsoid equation [12, 13]. 
Dual X-ray Absorptiometry (DXA)
Lumbar spine, hip, and forearm DXA (Hologic Delphi A; Hologic 
Inc., USA) was performed at baseline (before surgery) for all study 
Table 1. Baseline characteristics of the study participants




Age [years] 54.6 ± 1.8
Gender (women: men) 41:1
PTH [pg/mL] 490.4 ± 189.9 15–65
Serum total calcium [mg/dL] 11.9 ± 0.2 8.4–10.2
Serum phosphate [mg/dL] 2.4 ± 0.1 2.3–4.7
Urine calcium [mg/24 h] 318.6 ± 31.2 < 300
FGF23 [pg/mL] 75.55 ± 3.39 < 220 
25(OH)D3 [ng/mL] 16.2 ± 1.5 ≥ 30









Lumbar spine T-score –2.45 ± 0.2 ≥ –1
Femoral neck T-score –1.67 ± 0.2 ≥ –1
33% radius T-score –2.75 ± 0.3 ≥ –1
Fragility fractures (yes: no) 5:37
Adenoma volume [mL] 3.1 ± 0.5
Continuous data are expressed as mean ± standard error of the mean 
PTH — parathyroid hormone; FGF23 — fibroblast growth factor 23;  
25(OH)D3 — vitamin D; P1NP — total procollagen type 1 N-terminal propeptide; 
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for patients with PHPT, PTH levels were increased 
(490.4 ± 189.9 pg/mL), and 25(OH)D3 levels were in the 
range of deficiency (16.2 ± 1.5 ng/mL) (Tab. 1). 
At baseline (preoperatory), FGF23 was negatively 
and significantly correlated with PTH (r = –0.37, 
p = 0.038) but not with 25(OH)D3, serum Ca, or P 
(Fig. 1). Fibroblast growth factor 23 was not significantly 
related to baseline urine Ca or P (data not shown). 
Both PTH and FGF23 significantly correlated with 
the volume of the parathyroid adenoma, but the na-
ture of the relationship was different for each of them 
(r = 0.42, p < 0.05 for PTH and r = –0.34, p < 0.05 for 
FGF23). 
Mean serum PTH decreased to normal values 
one day after surgery (32.6 ± 4.38 pg/mL, p < 0.001 
versus preoperatory) in parallel with the normali-
sation of serum Ca (9.77 ± 0.19 mg/dL, p < 0.0001 
vs. preoperatory) (Fig.  2). However, mean serum 
FGF23 levels remained unchanged (81.69 ± 4.67 
pg/mL, p = non-significant) (Fig. 2). Mean serum P 
had a tendency to increase immediately after surgery, 
but the difference did not reach statistical significance 
(2.52 ± 0.11 mg/dL, p = non-significant) (Fig. 2). The 
postoperative change of FGF23 did not correlate 
with changes in PTH, Ca, or P (data not shown). 
Also, there were no significant differences regarding 
baseline biochemical markers and their postoperative 
changes (PTH, Ca, P, 25[OH]D3) between patients 
in whom FGF23 increased versus those in whom 
FGF23 decreased (data not shown). No significant 
predictors for FGF23 decrease were found. During 
the one-year follow-up in 13 patients (all under vita-
min D3 replenishment), 25(OH)D3 levels normalised 
(mean 25[OH]D3 serum concentration at 12 months 
post-operatory of 29.89 ± 3.84 ng/mL, p < 0.05), but 
FGF23 levels remained unchanged 12 months after 
surgery (80.9 ± 11.03 pg/mL, p = non-significant) 
(Fig. 3). Serum PTH completely normalised after one 
year (Fig. 3).
Almost half of the patients (n = 25) had osteopo-
rosis at baseline. FGF23 did not differ significantly 
between osteoporotic and non-osteoporotics patients 
(71.9 ± 26.3 pg/mL vs. 75.94 ± 20.7 pg/mL, p = 0.89). 
FGF23 levels were not related to BMD, T-scores at the 
level of the lumbar spine, hip, and 33% radius or to CTx 
and P1NP in the whole group (data not shown) or in 
the osteoporotics group (Tab. 2). However, FGF23 was 
negatively correlated with femoral neck T-score (strong 
correlation) and with P1NP (moderate correlation) in 
the PHPT non-osteoporosis patients (Tab. 2), but the 
associations were no longer significant when adjusted 
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Figure 1. Correlations between fibroblast growth factor 23 (FGF23) and parathormone (PTH), vitamin D (25(OH)D3), calcium, and 
phosphate in patients with primary hyperparathyroidism (PHPT). Ca — calcium; P — phosphate; PHPT — primary hyperparathyroidism; 
NS — non-significant; r — correlation coefficient
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Figure 2. The evolution of the serum parameters after surgery (p-value for pre-versus post-operatory). Ca — calcium; 









































































Figure 3. One-year follow-up outcomes in 13 patients (mean ± standard error of the mean). Ca — calcium; preop — preoperatory; 
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Discussion
FGF23 did not vary considerably after the resection of 
the parathyroid adenoma in PHPT patients with vita-
min D deficiency in our study, even after the normalisa-
tion of Ca metabolism and despite vitamin D supple-
mentation. FGF23 was not significantly correlated with 
25(OH)D3, Ca, and P. Although FGF23 was initially 
negatively related to bone parameters (femoral neck 
bone mass and P1NP) in the non-osteoporotic PHPT 
patients, the associations were lost after adjustment 
for PTH. The relationships that we identified between 
FGF23 and PTH or between FGF23 and the volume of 
the parathyroid adenoma seem rather an epiphenom-
enon, with the biological action of FGF23 largely taken 
over by the excessive PTH secretion. 
Murine models of PHPT exhibit significantly higher 
levels of FGF23 compared to wild type mice. In these 
animal models, FGF23 is positively correlated with 
serum Ca and negatively correlated with serum P at 
baseline, while significantly decreasing after the surgical 
excision of the parathyroid glands; this suggests a causal 
relationship between increased Ca/PTH and increased 
FGF23 levels [14].  
However, the few clinical studies addressing FGF23 
in PHPT have failed to uniformly demonstrate a signifi-
cant variation of FGF23 concentrations according to the 
presence or the cure of PHPT. Despite recording both 
higher [7, 8] and similar [9] levels of FGF23 in PHPT 
patients compared to controls and a significant decrease 
of FGF23 6 hours after surgery [7], initial clinical studies 
reported no significant changes of FGF23 on day 1, 6, 
and 7 after parathyroidectomy in PHPT patients with 
normal renal function [7–9]. 
More recent clinical data demonstrated a sig-
nificant six-week postoperative decrease in FGF23 
concentrations in 150 PHPT patients who underwent 
parathyroidectomy; however, besides being vitamin 
D replete, patients with abnormal renal function 
(creatinine clearance down to 40 ml/min) were also 
allowed to enter the study [6]. Although Yamashita et 
al. [8] also initially found higher FGF23 levels in PHPT 
compared to normal controls, this was no longer the 
case when only normal renal function PHPT patients 
were analysed [8]. 
Witteveen et al. [4] observed significantly higher 
FGF23 concentrations in 21 untreated PHPT patients 
compared to 24 euparathyroid patients cured after 
successful parathyroidectomy; they were all vitamin 
D replete, while the studied PHPT group was rather 
heterogeneous because it also included familial forms 
of PHPT, such as type 1 multiple endocrine neoplasia, 
and was compared to a different control group, not to 
their own evolution after surgery — as we did in the 
current research. The cross-sectional character of their 
study also conferred clear interpretative limitations [4].
The higher FGF23 concentrations before surgery 
compared to different control groups in some studies 
was explained in the context of PTH-induced hyper-
production of 1,25(OH)2D3, which in turn induces 
FGF23 expression as a counter-regulatory mechanism 
for the “danger” of an eventual hyperphosphataemia 
[15]. FGF23 was, indeed, negatively associated with 
1,25(OH)D3 levels in the study of Witteveen et al. [4]. 
These authors also found a positive correlation between 
FGF23 and PTH levels, but only when PHPT patients 
and surgically cured patients with normal parathyroid 
function were analysed together; when taken sepa-
rately, the significant relationship between PTH and 
FGF23 was not evident anymore [4]. However, they 
used an intact FGF23 assay, which has a significantly 
higher intra-individual variation and does not detect 
the biologically active C-terminal fragment, compared 
to the C-terminal FGF23 assay [16] that we used in our 
study.
The entire mechanism through which FGF23 regu-
lates PTH secretion still awaits clarification. A direct 
(vitamin D-independent) stimulating effect of PTH 
upon FGF23 has been suggested, especially in condi-
tions associated with excessive PTH production [15, 17]. 
On the other hand, other lines of evidence demonstrate 
a klotho-independent FGF23 suppressive effect upon 
PTH secretion in parathyroid cells [18]. This may partly 
explain the negative correlation found by us between 
PTH and FGF23 in our 42 patients with sporadic solitary 
parathyroid adenomas. 
Table 2. Correlation coefficients (followed by p-value) 
between fibroblast growth factor 23 (FGF23) and calcium 
and phosphate metabolism parameters and bone mass, 
respectively, in primary hyperparathyroidism (PHPT) with 
osteoporosis vs. PHTPT without osteoporosis patients
Variable
Osteoporosis  
(n = 25) 
FGF23
Without osteoporosis 
(n = 17) 
FGF23
Ca –0.11 (p = 0.68) –0.24 (p = 0.4)
P 0.1 (p = 0.63) 0.06 (p = 0.85)
PTH –0.11 (p = 0.65) –0.34 (p = 0.28)
25(OH)D3 –0.06 (p = 0.8) 0.49 (p = 0.08)
Lumbar T-score –0.37 (p = 0.13) 0.14 (p = 0.78)
Femoral neck T-score –0.27 (p = 0.26) –0.9 (p = 0.037)
Radius 33% T-score –0.09 (p = 0.7) 0.32 (p = 0.48)
CTx 0.27 (p = 0.28) 0.41 (p = 0.21)
P1NP 0.17 (p = 0.49) –0.61 (p = 0.047)
Ca — calcium; P — phosphate; PTH — parathormone; 25(OH)D3 — vitamin D; 
CTx — C-terminal telopeptide of type I collagen; P1NP — total procollagen type 
1 N-terminal propeptide
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Primary hyperparathyroidism reflects a new “set 
point” of the PTH-calcitriol-FGF23-klotho relationship. 
Walker et al. [19] demonstrated that D hypovitaminosis 
modifies the biochemical expression spectrum of PHPT 
[19]. Most of our patients had mild to severe D hypovi-
taminosis before surgery. However, we did not assess 
1,25(OH)2D3 levels in our patients, but it is known 
that most patients with D hypovitaminosis exhibit 
normal levels of 1,25(OH)2D3 in the setting of normal 
renal function [20]. One may argue that 25(OH)D3 
deficiency in our study may have blunted the effect of 
increased calcitriol levels upon FGF23 and led to “false 
normal” concentrations of FGF23. Nevertheless, mild 
D hypovitaminosis does not lead to low 1,25(OH)2D3 
[21]. Calcitriol has a serum concentration approximately 
1000-fold less than serum 25(OH)D3; therefore, little 
substrate is needed to ensure normal circulating levels 
of 1,25(OH)2D3 [22]. Some papers even found that 
lower 25-hydroxyvitamin D is linearly associated with 
higher 1,25-dihydroxyvitamin D levels in PHPT [19]. 
Moreover, in our study, FGF23 levels remained un-
changed after 12 months of follow-up, despite vitamin D 
supplementation and significant increases in 25(OH)D. 
Although not assessed in our study, several lines of evi-
dence indicate that klotho expression is down-regulated 
in parathyroid cells independently of PTH and with no 
changes in the expression of FGFR1, and it positively 
correlates with serum P and creatinine [23, 24]. The 
role of klotho in the pathophysiology of PHPT remains 
unclear, especially because not all research [25] found 
significant klotho expression dysregulation in human 
parathyroid tissue. 
A positive correlation between PTH levels and the 
volume of the parathyroid adenoma has been described 
in PHPT [26]. The inverse relationship between FGF23 
and the volume of the parathyroid adenoma probably 
mirrors the FGF23-PTH negative crosstalk rather than 
a direct effect of FGF23 on the tumour.
Although the FGF23–Ca interplay remains elusive 
in PHPT patients, the few independent positive as-
sociations [7, 8] were only reported in the preopera-
tive setting, and FGF23 levels remain fundamentally 
unchanged after parathyroidectomy, despite normali-
sation of serum Ca [7–9], including in our study. Fur-
thermore, Nilsson et al. [6] proved that the potential 
association between FGF23 and serum Ca is weakened 
by PTH [6]. The parathyroid FGF23 expression is also 
not related to serum Ca concentration [23]. FGF23 is 
not independently related to P in any of the studies [4, 
7–9], including ours. It also failed to demonstrate any 
regulatory effect upon urinary P in the absence of PTH 
[17]. It is actually klotho — and not FGF23 — expression 
level in the parathyroid glands that is associated with 
serum P [23]. PTH upregulates klotho expression in the 
renal tubuli, making them responsive to FGF23 and thus 
highlighting the importance of PTH for renal phosphate 
elimination [17]. Thus, it is probably only the P retention 
in the setting of secondary hyperparathyroidism that 
causes increments in FGF23 production and secretion, 
as is observed in chronic kidney disease [27].To our 
knowledge, our study is among the first to investigate 
noteworthy connections between FGF23 and bone 
metabolism in PHPT patients: FGF23 is supposed to 
suppress bone formation via Wnt signalling inhibition, 
and to stimulate RANKL expression synergic to PTH 
[10, 11]. We initially found significant negative correla-
tions between FGF23 and bone mass and metabolism 
parameters only in PHPT patients without osteoporosis, 
and not in the whole group, nor in the PHPT patients 
with osteoporosis. However, the associations were lost 
when PTH was taken into analysis. A very recent study 
on PHPT mice demonstrated that the bone transcrip-
tion of FGF23 is virtually enhanced by PTH via the at-
tenuation of dentin matrix protein 1 (DMP1), a critical 
element in bone mineralisation [28]. It is, thus, the PTH 
that has deleterious bone effects, while FGF23 bone 
production and its correlation with PTH seem to be 
merely an epiphenomenon.
The interpretation of our results is limited by the 
small number of subjects available for follow-up and the 
absence of a control group. However, we did investigate 
the hormonal profile of PHPT in a real-life setting of 
hypovitaminosis D — a prevalent dysfunction in the 
modern world [29]. Our study is also among the first to 
investigate the relationship between FGF23 and bone 
metabolism in PHPT patients.
Conclusions
FGF23 levels are not significantly changed by au-
tonomous PTH hypersecretion in patients associating 
D hypovitaminosis and are not influenced by the 
surgical excision of the adenoma. The importance of 
FGF23 in the regulation of Ca and P metabolism may 
be eluded by excessive PTH secretion in the presence 
of low vitamin D levels. We think that, contrary to 
secondary hyperparathyroidism, FGF23 measure-
ment cannot be considered a criterion in assessing 
the severity of PHPT.
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